HOUSTON, Texas, Dec 19, 2022 – Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLAG) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.
Download the full article: Invectys.Joint_.INDclearance.IVS3001.CTMC_MDA-clean-12.19.22-Final69.pdf